Today: 9 June 2026
Browse Category

NSE:ERIS 9 December 2025 - 10 December 2025

Biggest Stock Losers Today in India (10 December 2025): Kaynes Tech, IndiGo, Eris Lifesciences, Paytm Drag NSE & BSE

Biggest Stock Losers Today in India (10 December 2025): Kaynes Tech, IndiGo, Eris Lifesciences, Paytm Drag NSE & BSE

Kaynes Technology fell nearly 8% to ₹3,990 by midday Wednesday, extending a five-day slide after Kotak flagged financial disclosure concerns. The Sensex hovered near 84,645 (‑0.03%) and Nifty 50 was flat, while midcap and smallcap indices slipped about 0.4% and 0.2%. IT and PSU bank stocks dragged, while metals, auto, and realty shares edged higher.
10 December 2025
····
Top Gainers in Indian Stock Market Today (9 December 2025): Advent Hotels, Kaynes Technology, Tata Teleservices Shine Despite Sell‑Off

Top Gainers in Indian Stock Market Today (9 December 2025): Advent Hotels, Kaynes Technology, Tata Teleservices Shine Despite Sell‑Off

Advent Hotels International surged nearly 15% intraday on the NSE, leading gainers as Indian benchmarks Sensex and Nifty fell sharply on December 9. The Nifty hovered below 25,900, down 0.3–0.4%, while the Sensex dropped over 600 points amid foreign investor outflows and rupee weakness. Kaynes Technology and Tata Teleservices (Maharashtra) also posted strong gains.
9 December 2025
·····

Stock Market Today

  • Amgen (AMGN) Stock Analysis: Is It Still Undervalued After Strong Multi-Year Gains?
    June 9, 2026, 9:58 AM EDT. Amgen's stock has appreciated by 68.7% over five years, closing recently at $345.73. Despite robust share price gains, a Discounted Cash Flow (DCF) analysis indicates the stock is 48.3% undervalued, with an intrinsic value estimate of $668.86 per share based on projected future cash flows. The model uses Free Cash Flow to Equity, forecasting growth through 2035. Amgen trades at a price-to-earnings (P/E) ratio of 23.92x, reflecting market expectations for earnings and risk. Investors are reassessing Amgen's fair value amid its steady growth and large-cap biotechnology sector position, as it delivers a one-year return of 21.4%, slightly lagging peers. The findings suggest potential investment opportunities despite past strong performance.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop